News
SXTPW
0.0324
+28.06%
0.0071
Weekly Report: what happened at SXTP last week (0914-0918)?
Weekly Report · 5d ago
60 Degrees Advances Babesiosis Treatment With FDA Submission
TipRanks · 09/14 20:32
60 Degrees Pharmaceuticals Says It Submitted Statement Of Interest To FDA For Commissioner's National Priority Voucher For ARAKODA In Babesiosis; DSMB Interim Analysis Of Phase 2 Trial Scheduled October 1, Targets sNDA Submission In March-April 2027
Benzinga · 09/14 20:11
Weekly Report: what happened at SXTP last week (0907-0911)?
Weekly Report · 09/14 10:14
60 Degrees Pharmaceuticals Updates Strategy for Tick-Borne Diseases
TipRanks · 09/08 21:07
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 09/08 21:06
Weekly Report: what happened at SXTP last week (0831-0904)?
Weekly Report · 09/07 10:08
60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference
Barchart · 09/03 07:04
Weekly Report: what happened at SXTP last week (0824-0828)?
Weekly Report · 08/31 10:14
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 08/27 21:07
Weekly Report: what happened at SXTP last week (0817-0821)?
Weekly Report · 08/24 10:15
Analysts’ Opinions Are Mixed on These Healthcare Stocks: OmniAb (OABI), Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
TipRanks · 08/17 15:30
Weekly Report: what happened at SXTP last week (0810-0814)?
Weekly Report · 08/17 10:16
60 Degrees Pharma Q2 Net Loss Widens Despite 106% Product Revenue Growth; Stock Up
NASDAQ · 08/17 09:23
60 Degrees Q2 EPS $(0.90) Misses $(0.86) Estimate, Sales $56.798K Miss $186.000K Estimate
Benzinga · 08/14 19:48
Press Release: 60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
Dow Jones · 08/14 19:47
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
Barchart · 08/14 14:47
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 08/11 21:06
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates
NASDAQ · 08/11 00:05
Weekly Report: what happened at SXTP last week (0803-0807)?
Weekly Report · 08/10 10:11
More
Webull provides a variety of real-time SXTPW stock news. You can receive the latest news about 60 Degrees Pharm through multiple platforms. This information may help you make smarter investment decisions.
About SXTPW
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.